Is Bio Over? Target Q4 | Cho Hee-jin, Hana Securities Apgujeong Financial Center PB

Is Bio Over? Target Q4 | Cho Hee-jin, Hana Securities Apgujeong Financial Center PB [Double Crew]
Watch on YouTube ↗  |  July 24, 2026 at 01:16  |  15:41  |  3PRO TV (삼프로TV)
Speakers
Cho Hee-jin — Deputy Manager

Summary

Cho Hee-jin, a PB at Hana Securities, analyzes the Korean biotech sector and presents ABL Bio as a stock to study now for a potential Q4 rally. She details ABL Bio's brain shuttle platform technology, strong balance sheet, big pharma partnerships, and upcoming catalysts, while cautioning against buying immediately.

  • Biotech sector rotated from platforms to self-trial companies after Alteogen shock, but is now returning to profitable platform firms.
  • ABL Bio owns a proprietary brain shuttle technology (Grabody-B) with patent protection and multiple big pharma deals (Lilly, GSK, Sanofi).
  • The company holds 180 billion won in cash and a self-owned building worth 150 billion won, minimizing funding risk.
  • Stock has fallen ~70% from highs; a partner pipeline removal is a delay not a termination, with follow-up trials being prepared.
  • Near-term catalysts: FDA meeting for pancreatic cancer next month, milestone payments, and KOSDAQ promotion system from January 2025.
  • Speaker recommends watching ABL Bio and waiting for Q4 biotech momentum rather than entering at the current weak moment.
Ideas
Cho Hee-jin Deputy Manager 0:49
Moated biotech ABL Bio for Q4 watch
ABL Bio (298380.KQ) is a biotech platform company with a proprietary brain shuttle technology (Grabody-B) that efficiently delivers drugs across the blood-brain barrier, protected by patents and validated by deals with big pharma including Lilly, GSK, and Sanofi. The company has strong financials: 180 billion won in cash and a self-owned building worth 150 billion won, reducing dilution risk. The stock has fallen about 70% from highs due to sector weakness and a partner removing a pipeline, but the company clarifies it's a delay with a follow-up trial in preparation, not a termination. Near-term catalysts include an FDA meeting for pancreatic cancer next month, potential milestone payments from existing deals, and the KOSDAQ promotion system starting January 2025. The speaker believes good biotechs will recover after the bubble purge and that ABL Bio's valuation is cheap relative to a ~10 trillion won total milestone potential. However, she advises not to buy immediately but to study the stock now and wait for a biotech rally in Q4 when the water comes in.
298380.KQ HIGH
Up Next
3:03:25
[July 24 #BeforeMarketOpen] Oil Prices Surge Due to Red Sea Tanker Attack, New York Stock Market Falls / Alphabet, Tesla Plummet on Capital Expenditure Concerns, SK Hynix, Micron Rise
815 Money Talk (815머니톡) · Jul 24
30:33
Hold Rather Than Sell Now? The Most Important Checkpoints in a Rebound Market | Yoon Jeong-sik, Baro Asset Management Managing Director [Double Check]
3PRO TV (삼프로TV) · Jul 24
42:15
Will the August stock market sentiment change? Now, more important than semiconductors is 'supply and demand spread' | Park Byeong-chang, MP Partners CEO [Market Inside]
3PRO TV (삼프로TV) · Jul 24
20:09
Why Kalshi's Rough Week Could Reach the Supreme Court: DEX in the City
Unchained (Chopping Block) · Jul 23
12:59
O EMBATE ENTRE CAZÉTV E GLOBO NA COPA DO MUNDO FOI SÓ O COMEÇO
Market Makers · Jul 23

This 3PRO TV (삼프로TV) video, published July 24, 2026, features Cho Hee-jin discussing 298380.KQ. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: Cho Hee-jin  · Tickers: 298380.KQ